Targeting neuroinflammation to treat progressive neurologic disorders is a rational neuroprotective strategy but to realize the potential of such approaches, the cellular and molecular pathways critical for disease-associated neuroinflammation must be identified.11 Our recent report indicates that Nlrp3 is required for the development of inflammatory symptoms and neurodegeneration in a mouse model of PD.17 Here we evaluated the expression of NLRP3 in human tissues obtained from histopathologically confirmed cases of idiopathic PD and control subjects. The gene discussed is NLRP3; the disease is Parkinson disease.